Almirall Articles
The solution for Spanish pharma companies lies abroad
13 March 2013
Forest launches COPD product Tudorza in USA
12 December 2012
EU approvals for Viread and Constella; EMA accepts vintafolide MAA
29 November 2012
EMA backs Almirall's Constella; Bayer's Eylea recommended by CHMP
24 September 2012
Denmark sees first launches of Almirall's Eklira Genuair and ViroPharma's Plenadren
21 September 2012
Almirall gains rights for IBS drug linaclotide in Mexico
10 September 2012
Almirall sets up first direct North America presence
5 September 2012
Almirall says Eklira Genuair provides meaningful and sustained bronchodilation from the first dose
4 September 2012
Credit Suisse focus on new drugs for COPD
19 August 2012
No proof of added benefit of Sativex, says German IQWiG
17 April 2012
GW Pharma and Almirall extend Sativex deal to Mexico
15 March 2012
Almirall looks to robust 2012 despite higher losses
28 February 2012
Bayer and Algeta’s Alpharadin efficacy confirmed; Almirall to market Xarelto in Spain
13 February 2012
GW Pharma’s Sativex cleared in Austria
7 February 2012
Almirall starts Ph III COPD trial; collaborates with BioFocus; and posts sales and earnings downturn
16 November 2011
US FDA accepts Ironwood and Forest’s NDA for IBS drug linaclotide; new data from Almirall
24 October 2011
Nycomed to market Almirall’s Kestine in Southeast Asia markets; files for linaclotide in EU
30 September 2011
Almirall enters integrated discovery agreement with Proteros
22 September 2011
Forest and Almirall see early filing of COPD drug aclidinium with US FDA; Appointment at Almirall
4 July 2011
Former EMA chief Lonngren teams up with NDA Group, which launches new unit; Almirall names R&D chief
18 January 2011
Almirall and Forest say their COPD drug aclidinium shows positive results and Ph III and Ph II studies
6 January 2011
Spain’s Almirall sees downturn in 3rd-qtr 2010 sales and incomes, but in line with guidance
16 November 2010
Almirall/Ironwood’s IBS drug linaclotide shows positive Ph III results
15 September 2010
Spain’s Almirall sees 1st half 2010 sales dip, hit by domestic austerity plan and economic environment
30 July 2010
Product marketing briefs from Merck & Co, Merck Serono, GW/Almirall, AstraZeneca and Roche
28 July 2010
EPO Rules European Patent for XenoPort’s XP13512 is valid; Almirall grants Eisai marketing rights to cinitapride in China
16 April 2010
Spain’s Almirall posts solid performance in 2009, setting basis for sustainable long-term growth
1 March 2010
Almirall rises on positive Ph III results for aclidinium in COPD, partnered with Forest; Likely FDA “no” to Forests’ Bystolic in CHF
8 January 2010
Almirall and Forest Labs to expand LAS100977 respiratory deal with $75 million upfront
17 December 2009
Spain’s Almirall sees third-quarter 2009 sales up 2.4%, with strong showing from dermatologicals
16 November 2009
Ironwood Pharma in deals for linaclotide with Spain’s Almirall and Japan’s Astellas
10 November 2009
UK pharma industry beset by economic and political pressures
3 November 2009
GW reveals strong Sativex data in multiple sclerosis
14 September 2009
New GW Pharma Shares Issued Raising $11.2m
6 August 2009
Almirall opens new UK office in London
3 June 2009
Almirall files Sativex in UK and Spain
28 May 2009
GW Pharma reports first ever profit
22 May 2009
Almirall profit up 41% on tax effects
15 May 2009
Almirall names Steve Webber as senior discovery director
23 April 2009
GW soars 51% on positive data from 3rd Ph III Sativex study; EU submission set for 2nd qtr
23 March 2009
Stock Commentary - New York week to Mar 9, 2009
16 March 2009
Further studies needed for aclidinium bromide
16 March 2009
GW jumps 16.6% on strong Sativex findings
2 March 2009
Almirall asthma drug shows strong results
2 March 2009
Almirall reports strong Ph IIa data on LABA drug
15 December 2008
Farmindustria slams EC generic blocking claims
8 December 2008
Almirall's nine-month profit jumps 5.3%
24 November 2008
Almirall to co-market Pfizer's Caduet in Spain under Astucor brand
17 November 2008
Almirall to co-market sitagliptin in Spain
10 November 2008
Almirall defies critics to progress COPD drug
27 October 2008
Stock Commentary - New York week to Sept 8, 2008
15 September 2008
Almirall tumbles 42% as COPD drug disappoints
15 September 2008
Spain's Almirall denies bid approach
8 September 2008
Almirall's first-half sales boosted by acquisitions
8 September 2008
Almirall and Proteros achieve milestone
28 July 2008
Almirall/Forest complete COPD trials
14 July 2008
Almirall reports Ph II data for COPD drug
2 June 2008
Almirall's 1st-qtr net income falls 9.9%
26 May 2008
Almirall sets up in Poland and Switzerland
12 May 2008
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
